By Anna C. Greene, PhD, NETRF Chief Scientific Officer A new open-access review article in Virchows Archiv, “Novel concepts of cell-of-origin in neuroendocrine neoplasms,” by
Jamie Metzl is a writer and technology/health care futurist who regularly speaks to the medical industry on the future of health care. When Jamie’s father,
The Neuroendocrine Tumor Research Foundation (NETRF) today announced its latest round of neuroendocrine cancer research grant recipients. The thirteen investigators receiving awards are pursuing innovative,
In November 2025, Drew Greenberg marked his Bar Mitzvah in a way that moved everyone who heard his story. At just 13 years old, Drew
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to share an important leadership transition within our Board of Scientific Advisors (BOSA), a group of distinguished
Highlights from recent clinical trial developments in neuroendocrine cancer Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly
By Anna C. Greene, PhD, NETRF Chief Scientific Officer One of the most exciting developments in neuroendocrine cancer treatment in recent years has been the
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we often hear a familiar story: symptoms that don’t
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and